RxDoctor Payments DataLook up a doctor →

George Nissan, DO

Internal Medicine · Chicago, ILNPI 1245222033

Payments from drug & device makers

$489,738in general payments, 2019–2025

Across 1,447 payments — averaging $338.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceutical Holding Company Ltd.$142K
  • Lilly USA, LLC$89K
  • Biohaven Pharmaceuticals, Inc.$63K
  • Amgen$47K
  • AbbVie$36K
  • Pfizer$35K
  • plus $77K from 54 others
$26,225in research payments, 2019–2025

Across 6 payments — averaging $4370.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$26K

What the payments were for

  • Consulting fees$51,95421%
  • Speaking & faculty fees$156,19062%
  • Grants$880%
  • Travel & lodging$14,1696%
  • Food & beverage$29,54812%
  • Education$3200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biohaven Pharmaceutical Holding Company Ltd.69$142,234
Lilly USA, LLC250$89,476
Biohaven Pharmaceuticals, Inc.56$62,620
Amgen(2 entities)190$47,159
AbbVie(2 entities)226$36,116
Pfizer55$35,061
Teva Pharmaceuticals USA, Inc.96$19,999
Biodelivery Sciences International, Inc.14$10,091
Collegium Pharmaceutical, Inc.5$8,380
Lundbeck LLC49$7,927
H. Lundbeck A S2$7,229
Currax Pharmaceuticals LLC15$5,055
Promius Pharma LLC7$4,334
Amneal Pharmaceuticals LLC5$3,066
Tonix Medicines, Inc.15$2,309
MDD US Operations, LLC9$1,091
Merz Pharmaceuticals, LLC23$760
Novartis27$474
Axsome Therapeutics, Inc.12$431
UCB, Inc.25$385
Impel Pharmaceuticals Inc.23$383
Upsher-smith Laboratories LLC18$359
Supernus Pharmaceuticals, Inc.19$343
Ipsen Biopharmaceuticals, Inc22$339
Bausch Health US, LLC16$326
Genentech USA, Inc.12$279
Impel Pharmaceuticals LLC13$272
Merz North America, Inc.12$255
Avanir Pharmaceuticals, Inc.20$248
Sanofi12$216
EMD Serono, Inc.10$210
Grifols USA, LLC11$209
Biogen9$182
Neurocrine Biosciences, Inc.7$158
Sunovion Pharmaceuticals Inc.7$132
AstraZeneca6$132
Bristol Myers Squibb2$132
Takeda Pharmaceuticals U.S.A., Inc.8$131
Assertio Therapeutics, Inc.15$112
Revance Therapeutics, Inc.1$105
Endo Pharmaceuticals Inc.6$95
Harmony Biosciences LLC5$87
Vanda Pharmaceuticals Inc.3$82
Otsuka America Pharmaceutical, Inc.4$75
Scilex Pharmaceuticals Inc.4$73
SK Life Science, Inc.3$68
Zyla Life Sciences, Inc.3$63
Merck3$59
Eisai Inc.3$57
Johnson & Johnson1$37
Mallinckrodt Enterprises LLC2$37
Arbor Pharmaceuticals, Inc.3$37
Argenx US, Inc.1$32
Idorsia Pharmaceuticals US Inc2$31
Shire North American Group Inc2$27
Livanova USA, Inc.1$26
Banner Life Sciences, LLC1$23
Optinose US, Inc.1$19
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$19
Vertical Pharmaceuticals, LLC1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$489,738 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$56,534
Medicare patients
87
Services billed
4,002

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate19$35,843
Emgality PenGalcanezumab-Gnlm34$27,743
UbrelvyUbrogepant26$26,332
Aimovig AutoinjectorErenumab-Aooe35$26,031
QuliptaAtogepant15$17,907
Levetiracetam ErLevetiracetam13$1,581
Diphenhydramine Hcl32$797
Amitriptyline Hcl20$533
Gabapentin26$515
Topiramate23$375
Venlafaxine Hcl ErVenlafaxine Hcl11$298
Tizanidine Hcl57$298
Duloxetine Hcl16$293
Acetazolamide11$274
Baclofen28$261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$36,116$44,23841 claims
PfizerNurtec Odt$35,061$35,84319 claims
Upsher-smith Laboratories LLCTopiramate$359$37523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →